Neuroimaging standards for research into small vessel disease—advances since 2013

Marco Duering, Geert Jan Biessels, Amy Brodtmann, Christopher Chen, Charlotte Cordonnier, Frank Erik de Leeuw, Stéphanie Debette, Richard Frayne, Eric Jouvent, Natalia S. Rost, Annemieke ter Telgte, Rustam Al-Shahi Salman, Walter H. Backes, Hee Joon Bae, Rosalind Brown, Hugues Chabriat, Alberto De Luca, Charles deCarli, Anna Dewenter, Fergus N. DoubalMichael Ewers, Thalia S. Field, Aravind Ganesh, Steven Greenberg, Karl G. Helmer, Saima Hilal, Angela C.C. Jochems, Hanna Jokinen, Hugo Kuijf, Bonnie Y.K. Lam, Jessica Lebenberg, Bradley J. MacIntosh, Pauline Maillard, Vincent C.T. Mok, Leonardo Pantoni, Salvatore Rudilosso, Claudia L. Satizabal, Markus D. Schirmer, Reinhold Schmidt, Colin Smith, Julie Staals, Michael J. Thrippleton, Susanne J. van Veluw, Prashanthi Vemuri, Yilong Wang, David Werring, Marialuisa Zedde, Rufus O. Akinyemi, Oscar H. Del Brutto, Hugh S. Markus, Yi Cheng Zhu, Eric E. Smith, Martin Dichgans, Joanna M. Wardlaw

Producción científica: Review articlerevisión exhaustiva

144 Citas (Scopus)

Resumen

Cerebral small vessel disease (SVD) is common during ageing and can present as stroke, cognitive decline, neurobehavioural symptoms, or functional impairment. SVD frequently coexists with neurodegenerative disease, and can exacerbate cognitive and other symptoms and affect activities of daily living. Standards for Reporting Vascular Changes on Neuroimaging 1 (STRIVE-1) categorised and standardised the diverse features of SVD that are visible on structural MRI. Since then, new information on these established SVD markers and novel MRI sequences and imaging features have emerged. As the effect of combined SVD imaging features becomes clearer, a key role for quantitative imaging biomarkers to determine sub-visible tissue damage, subtle abnormalities visible at high-field strength MRI, and lesion-symptom patterns, is also apparent. Together with rapidly emerging machine learning methods, these metrics can more comprehensively capture the effect of SVD on the brain than the structural MRI features alone and serve as intermediary outcomes in clinical trials and future routine practice. Using a similar approach to that adopted in STRIVE-1, we updated the guidance on neuroimaging of vascular changes in studies of ageing and neurodegeneration to create STRIVE-2.

Idioma originalEnglish (US)
Páginas (desde-hasta)602-618
Número de páginas17
PublicaciónThe Lancet Neurology
Volumen22
N.º7
DOI
EstadoPublished - jul 2023

ASJC Scopus subject areas

  • Clinical Neurology

Huella

Profundice en los temas de investigación de 'Neuroimaging standards for research into small vessel disease—advances since 2013'. En conjunto forman una huella única.

Citar esto